140130-10-5

Upstream product

• 501031-13-6 N-[1-acetyl-4-(trimethylsilyl)but-3-ynyl]benzamide 
• 6813-61-2 2-(benzoylamino)-4-pentynoic acid 
• 140130-09-2 4-benzoylamino-1-hexyn-5-one 

Downstream Products

• 132646-34-5 2-(5-methyl-2-phenyl-4-oxazolyl)methyl-5-benzofurancarboxaldehyde 
• 181931-87-3 3-[2-(5-Methyl-2-phenyl-oxazol-4-ylmethyl)-benzofuran-5-yl]-propionaldehyde 
• 140130-11-6 4-{5-[(2-methoxyvinyl)-5-benzofuran-2-yl]methyl}-5-methyl-2-phenyloxazole 
• 181931-77-1 (E)-3-[2-(5-Methyl-2-phenyl-oxazol-4-ylmethyl)-benzofuran-5-yl]-acrylic acid 
• 181931-88-4 4-(5-Diethoxymethyl-benzofuran-2-ylmethyl)-5-methyl-2-phenyl-oxazole 
• 140130-12-7 5-(2,2-dimethoxyethyl)-2-[(5-methyl-2-phenyl-4-oxazolyl)methyl]benzofuran 
• 181931-92-0 Ethoxy-[2-(5-methyl-2-phenyl-oxazol-4-ylmethyl)-benzofuran-5-yl]-acetonitrile 
• 140130-13-8 2-Methoxy-3-[2-((5-methyl-2-phenyl-4-oxazolyl)-methyl)benzofuran-5-yl]propanenitrile 
• 1028266-72-9 4-[5-(2,2-Diethoxy-ethyl)-benzofuran-2-ylmethyl]-5-methyl-2-phenyl-oxazole 
• 1027189-58-7 4-[5-(2,2-Bis-allyloxy-ethyl)-benzofuran-2-ylmethyl]-5-methyl-2-phenyl-oxazole 
• 181931-89-5 4-[5-(3,3-Diethoxy-propyl)-benzofuran-2-ylmethyl]-5-methyl-2-phenyl-oxazole 
• 181931-91-9 2-ethoxy-4-{2-[(5-methyl-2-phenyloxazol-4-yl)-methyl]benzofuran-5-yl}butyronitrile 
• 1025987-85-2 4-[5-(2,2-Dipropoxy-ethyl)-benzofuran-2-ylmethyl]-5-methyl-2-phenyl-oxazole 

Relevant academic research and scientific papers

Effects of modifications of the linker in a series of phenylpropanoic acid derivatives: Synthesis, evaluation as PPARα/γ dual agonists, and X-ray crystallographic studies

A new series of α-aryl or α-heteroarylphenyl propanoic acid derivatives was synthesized that incorporate acetylene-, ethylene-, propyl-, or nitrogen-derived linkers as a replacement of the commonly used ether moiety that joins the central phenyl ring with

Antidiabetic agents

The present invention provides compounds of Formula (I): wherein A, X, Q, Y, B, D, Z, and E have any of the values defined in the specification, and pharmaceutically acceptable salt thereof, that are useful as antidiabetic agents. Also disclosed are pharmaceutical compositions comprising one or more compounds of Formula I, processes for preparing compounds of Formula I, and intermediates useful for preparing compounds of Formula I.

Hypoglycemic activity of a series of α-alkylthio and α-alkoxy carboxylic acids related to ciglitazone

The thiazolidinedione moiety of ciglitazone and its analogues can be replaced by an α-alkoxy or α-thioether carboxylic acid group. The influence of the nature of the R group, the length of the connector to the aromatic backbone of the molecule, and the stereochemistry have been studied. The most potent compounds have glucose-lowering activity at doses as low as 0.01 mg/kg.

3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives

A method of using certain 3-aryl-2-hydroxypropionic acid derivatives and analogs in the treatment of hypertension.

3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents

Certain 3-(phenyl, chroman-2-yl, benzofuran-5-yl, or benzoxazol-5-yl)-2-(hydroxy or mercapto)propionic acid derivatives and analogs are useful as hypoglycemic and hypocholesterolemic agents.